ArticleBMC research notes2026
Association between Epstein-Barr virus capsid antigen IgA positivity and increased risk of chronic obstructive pulmonary disease: a retrospective cohort study.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEpstein-Barr virus (EBV) is a highly prevalent DNA virus linked to malignancies, autoimmune, and chronic inflammatory diseases. Elevated Epstein-Barr Virus Capsid Antigen IgA (EB‑VCA IgA) has been reported in diseases such as nasopharyngeal carcinoma and Sjögren’s syndrome; however, its relationship with chronic obstructive pulmonary disease (COPD) remains unclear.
methodsThis retrospective cohort study included 2497 individuals who underwent EB-VCA IgA testing at Cheng Hsin General Hospital between 2013 and 2022. Baseline clinical data, laboratory findings, and comorbidities were analyzed. Logistic regression and Cox proportional hazards models were used to evaluate the association between EB-VCA IgA positivity and COPD risk, adjusting for sex, age, and body mass index (BMI). Individuals with pre-existing COPD were excluded.
resultsAmong participants, 21% were EB-VCA IgA positive. The positive group had significantly lower hemoglobin levels (p = 0.005) but no differences in other baseline laboratory markers. EB-VCA IgA positivity was associated with increased COPD risk (adjusted OR = 1.86, p = 0.003). After excluding pre-existing COPD cases, EB-VCA IgA-positive individuals exhibited a 2.83-fold higher cumulative incidence of COPD (adjusted HR = 2.83, 95% CI 1.53–5.22). No association was found between EB-VCA IgA and acute COPD exacerbation (p = 0.859). Subgroup analyses demonstrated consistent results across clinical and demographic factors.
conclusionEB-VCA IgA positivity is significantly associated with increased COPD risk, underscoring the potential role of chronic EBV infection in COPD pathogenesis. Monitoring EB-VCA IgA levels may support early detection and personalized management of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.